Overview

A Study of ATI-50002 Topical Solution for the Treatment of Vitiligo

Status:
Completed
Trial end date:
2019-10-16
Target enrollment:
Participant gender:
Summary
The main objective of this study is to assess the safety, tolerability and efficacy of ATI-50002 Topical Solution, 0.46% in subjects with non-segmental facial vitiligo.
Phase:
Phase 2
Details
Lead Sponsor:
Aclaris Therapeutics, Inc.
Treatments:
Pharmaceutical Solutions